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IOP reduction (mean 39 to 53%) were statistically compara-
ble in the two groups. Considering postoperative complica-
tions, no relevant differences were found.  Discussion: Tra-
beculectomy and phacotrabeculectomy outcome did not 
show any differences between   -tocopherol-supplemented 
patients and the placebo group. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Filtering and nonfiltering procedures are still the main 
glaucoma surgeries of choice today. Despite their success, 
there is a steady rate of failure owing to progressive scar-
ring in the subconjunctival tissues. To overcome this 
problem, wound-healing-modifying agents are some-
times applied during surgery. Nevertheless, potential 
sight-threatening complications limit the generous use of 
mitomycin C in glaucoma procedures.
 In the search for antiscarring alternatives, Larrosa et 
al.  [1, 2] , Pinilla et al.  [3, 4 ] and our group  [5, 6] focused 
on compounds of the vitamin E family. Of these,   -to-
copherol,   -tocopheryl acetate,   -tocopheryl succinate, 
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 Abstract 
 Purpose: The vitamin E compound   -tocopherol inhibits fi-
broblast growth in vitro. To evaluate its potential benefit in 
preventing failure of glaucoma filtration surgery, we pro-
spectively investigated the outcome of filtering surgery with 
postoperative dietary   -tocopherol supplementation.  Pa-
tients and Methods: Thirty-nine patients (39 eyes) with pri-
mary open-angle glaucoma or pseudoexfoliative glaucoma 
were randomly assigned to two post-(phaco)-trabeculec-
tomy treatment groups. Daily oral intake of 300 mg   -to-
copheryl-acetate (absorbed as   -tocopherol in the intestine) 
for 2 months was compared to a placebo preparation in a 
double-blind trial. The follow-up time was 1 year. Success 
was defined as intraocular pressure (IOP)  ^  18 mm Hg with 
no medication, no needling revision, and no subconjuncti-
val injection.  Results: In the tocopherol group, the relative 
risk for trabeculectomy failure decreased from 1.58 at 2 
weeks (p = 0.95) to 1.0 at 1 year. Success rates (67–90%) and 
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and   -tocotrienol exhibited antiproliferative and antifi-
brotic effects in vitro and in a rabbit model of glaucoma 
filtration surgery  [1–6] .
 In this study, we report the results of our double-blind 
prospective study, where we hoped to modify the postop-
erative outcome of trabeculectomy or phacotrabeculec-
tomy with   -tocopherol dietary supplementation.
 Patients and Methods 
 Inclusion criteria of consecutive patients were medically un-
controlled primary open-angle or pseudoexfoliative glaucoma 
necessitating filtering surgery – with or without lens implanta-
tion. Progressive visual field changes associated with glaucoma 
and open anterior chamber angles in gonioscopy had to been 
proven.
 Exclusion criteria were legal blindness in the fellow eye, previ-
ous ocular surgery in either eye, laser trabeculoplasty within the 
last 6 months, neovascular glaucoma, drug addiction, known psy-
chiatric or intestinal diseases, fat malabsorption disease, vitamin 
E supplementation 3 months before surgery, and unsafe contra-
ception in young women. A detailed history, best corrected vi-
sual acuity, slit-lamp biomicroscopy with optic nerve head evalu-
ation and Goldmann applanation tonometry were recorded in all 
study participants the day before surgery.
 All patients were recruited in the Department of Ophthalmol-
ogy, Inselspital, University of Bern, and gave their written in-
formed consent before inclusion in the study. The study was ap-
proved by the local ethical committee and conformed to the pro-
visions of the Declaration of Helsinki.
 One surgeon performed all trabeculectomies as follows: in all 
cases, a fornix-based opening of the conjunctiva and Tenon’s cap-
sule, and a limbus-based 4  ! 4-mm scleral flap was prepared 
reaching the clear cornea. A sclerotomy containing the cornea 
and trabecular meshwork was done using a motor trephine (1.5 
mm in diameter). A peripheral iridectomy was always performed. 
After suturing of the scleral flap with two nylon 10-0 sutures, the 
conjunctiva was closed with two polyglactin 8-0 sutures and a U-
shaped nylon 10-0 suture at the 12 o’clock position. No mitomycin 
C or 5-fluorouracil was used during the surgical procedure. Post-
operative standard topical therapy included atropin (1%) oint-
ment for the first week and antibiotic-steroid ointment and drops 
(dexamethasone, neomycin and polymyxin B) initially 6 times 
daily which were then tapered off over 5 weeks.
 If a cataract with a visual acuity of less than 0.8 was present, a 
combined surgical procedure – phacotrabeculectomy – was of-
fered. After preparation of the scleral flap, a corneal tunnel start-
ing at the flap base was created followed by routine phacoemulsi-
fication (phaco-chop) with posterior chamber lens implantation. 
Sclerotomy, peripheral iridectomy, wound closure and postopera-
tive medical therapy were then performed as described above.
 Study participants were randomly assigned in a double-blind 
fashion to either the tocopherol or the control/placebo group. 
Subjects in the tocopherol group were treated with one 300-mg 
capsule of all-rac-  -tocopheryl acetate (Ephynal  , Bayer, Switzer-
land) daily for 2 months. Patients in the control group received 
identical-looking placebo capsules. Follow-up examinations were 
scheduled at 2 weeks, 2 months and 1 year postoperatively. Intra-
ocular pressure (IOP), filtering bleb appearance, postoperative 
complications and interventions were recorded.
 Successful trabeculectomy or phacotrabeculectomy was de-
fined as intraocular pressure (IOP)  ^  18 mm Hg with no antiglau-
comatous medication, no needling revision and no subconjuncti-
val injection. Success rates, IOP levels, and postoperative compli-
cations were compared between the tocopherol group and the 
control group 2 weeks, 2 months and 1 year postoperatively using 
Fisher’s exact test and the Mann-Whitney U test. The relative risk 
of trabeculectomy and phacotrabeculectomy failure was calcu-
lated. Differences with a first-order error of p  ! 0.05 were consid-
ered statistically significant.
 Results 
 A total of 41 patients (41 eyes) were included into the 
study: 19 participants were randomly assigned to the to-
copherol group, 22 to the control group. Two subjects had 
to be excluded on the first postoperative day before ini-
tiation of treatment due to anterior chamber bleeding 
(76-year-old female with pseudoexfoliative glaucoma; 
68-year-old male with primary open angle glaucoma). 
Both patients received a tissue plasminogen activator in-
jection.
 The demographic and clinical characteristics did not 
differ significantly between the 19 subjects of the tocoph-
erol group and the remaining 20 subjects of the control 
group ( table 1 ). However, patients in the tocopherol group 
had more frequently pseudoexfoliative glaucoma and 
tended to suffer from more advanced glaucoma (larger/
deeper visual field defects, higher preoperative IOP, more 
antiglaucomatous drugs preoperatively). On the other 
hand, patients in the control group had been on presur-
gical antiglaucomatous therapy for a longer period of 
time and had received a combined surgical procedure 
(phacotrabeculectomy) slightly more often.
 All study participants were repeatedly re-examined 
for at least 2 months after trabeculectomy or phacotra-
beculectomy at the Department of Ophthalmology, Uni-
versity of Bern. One-year follow-up was available for 
18/19 subjects of the tocopherol group and 18/20 subjects 
of the control group.
 Trabeculectomy and phacotrabeculectomy failures 
were as follows for the tocopherol group versus the con-
trol group: 3 versus 3 eyes at 2 weeks; 3 versus 2 eyes at 2 
months; 0 versus 1 eye at 1 year postoperatively. In the 
tocopherol group, 4 filtering blebs were encapsulat ed 
(and subsequently needled or/and injected with mitomy-
cin C) and 2 blebs were inconspicuous, whereas in the 
control group 4 blebs were encapsulated (and subsequent-
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ly needled and/or injected with mitomycin C), 1 flat and 
1 inconspicuous. In these 6 unsuccessful cases, the IOP 
ranged from 19 to 28 mm Hg in the tocopherol group and 
from 19 to 23 mm Hg in the control group. The relative 
risk ratio for trabeculectomy and phacotrabeculectomy 
failure decreased in the tocopherol group from 1.58 at 2 
weeks [95% confidence interval (CI) = 0.30–8.43] to 1.26 
at 2 months (95% CI = 0.46–3.46), and finally to 1.0 at 1 
year postoperatively (95% CI = 0.40–2.52).
 The success rates of trabeculectomy and phacotra-
beculectomy did not differ significantly between the two 
study groups (tocopherol vs. control): 84 versus 85% (n = 
19/20) at 2 weeks, 68 versus 75% (n = 19/20) at 2 months, 
and 67 versus 67% (n = 18/18) at 1 year postoperatively 
(Fisher’s exact test, two-tailed p = 0.731–1.0).  Figure 1 
presents the preoperative and postoperative IOP levels in 
successful trabeculectomy and phacotrabeculectomy 
cases in the two study groups ( fig. 1 ). On average, subjects 
in the tocopherol group had higher preoperative/pre-
treatment IOP and lower postoperative IOP levels com-
pared with the control group. At 2 weeks postoperatively, 
successful trabeculectomy and phacotrabeculectomy 
cases showed a decrease in IOP of 53.2  8 18.1% (mean  8 
SD) in the tocopherol group versus 43.8  8 17.6% in the 
control group (Mann-Whitney U test, two-tailed p = 
0.186). The decrease in IOP was 49.9  8 21.3% (tocoph-
erol) versus 39.1  8 20.5% (control) at 2 months postop-
Table 1. Demographic and clinical characteristics of the -tocopherylacetate and placebo-treated groups
Tocopherol (n = 19) Control (n = 20) p value1
Demographic characteristics
Female/male 9/10 8/12 0.751
Age, years 74.089.1 69.1811.7 0.121
Clinical characteristics
POAG/PXG 6/13 11/9 0.200
BCVA (decimal); mean and range 0.64; 0.05–1.0 0.66; 0.03–1.2 0.910
Refraction, SE, dptr –0.9183.62 –1.0383.15 0.683
Mean defect Octopus VF, dB 17.0388.03 11.4988.73 0.065
Loss variance Octopus VF, dB2 38.17830.29 25.19819.77 0.220
Duration of antiglaucomatous therapy before surgery, years 4.986.6 7.185.6 0.094
Preoperative number of antiglaucomatous drugs (maximum = 6) 2.681.1 2.281.2 0.175
Preoperative IOP, mm Hg 25.689.5 22.984.7 0.619
Trabeculectomy/combined trabeculectomy and lens implantation 14/5 12/8 0.501
Previous laser trabeculoplasty 4 7 0.480
POAG = Primary open angle glaucoma; PXG = pseudoexfoliative glaucoma; BCVA = best corrected visual acuity calculated by 
logMAR (log of the minimum angle of resolution) conversion; SE = spherical equivalent;  Octopus VF = visual field in automated pe-
rimetry (Octopus 101).
1 Two-tailed p by the Mann-Whitney U test and Fisher’s exact test.
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 Fig. 1. Graph illustrating the pre- and postoperative IOPs in the 
  -tocopheryl-acetate- and placebo-treated groups (mean IOP  8 
SD, mm Hg). 
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eratively (p = 0.200), and 47.3  8 19.6% versus 44.9  8 
13.6% at 1 year postoperatively (p = 0.670).
 A total of 7 eyes in the tocopherol group and 4 eyes in 
the control group were affected by postoperative compli-
cations (Fisher’s exact test for tocopherol vs. control, two-
tailed p = 0.301): 1 eye had prolonged hypotony alone in 
both groups, i.e. IOP  ^  5 mm Hg for at least 2 weeks; 1 
eye in each group showed wound leak alone, i.e. Seidel 
test was positive; 2 eyes in each group had wound leak and 
prolonged hypotony requiring resuturing (p  1 0.999 for 
all comparisons). In the tocopherol group, but not in the 
control group, 2 eyes showed transient peripheral choroi-
dal detachment (p = 0.231) and 1 eye had a flat anterior 
chamber (p = 0.487) ( table 2 ).
 Discussion 
 Failure of glaucoma surgery still confronts the clini-
cian with a dilemma. In most cases, medical therapy is 
reinstituted. A significant proportion of these patients 
are refractory to medical or laser therapy and further sur-
gery is the only option. To prevent this failure, different 
antifibrotic substances have been tested or are used intra- 
and postoperatively with a varying degree of success  [7] . 
So far, adequate evidence for the prevention of bleb fail-
ure has only been shown for mitomycin C  [8, 9] . How-
ever, because of its long-term local impairment of ocular 
healing and defense, mitomycin C can have serious sight-
threatening side effects. A study of the follow-up and 
complications of perioperative mitomycin C demonstrat-
ed that 10% had late bleb leak, 10% scleral necrosis, and 
5% hypotonous maculopathy  [10] . The incidence of 
endoph thalmitis after antimetabolite-treated trabeculec-
tomy is reported to be 1.1% for superior trabeculectomies 
and 8% for inferior trabeculectomies  [11, 12] .
 In an attempt at enlarging the therapeutic armamen-
tarium with a less toxic substance, we tested the hypoth-
esis of bleb failure prevention by adding 300 mg/day of 
systemic   -tocopheryl acetate in a double-blind study. 
Although the systemic route is unconventional in glau-
coma treatment, we opted for this approach.
 Fuller et al.  [13]  showed that the combination of sys-
temic antifibrotic drugs (prednisolone, colchicine and 
flufenamic acid or diclofenac) was able to prevent fibrosis 
and bleb failure without significant local or systemic side 
effects in patients with signs of threatened early bleb fail-
ure.
 In        nonsupplemented       humans,       plasma        -tocopher-
ol concentrations commonly vary between 20 and 35 
  mol/l. A daily dosage of 300 mg   -tocopheryl acetate 
(absorbed in the intestine as   ) was chosen since 2–3 
times increased plasma levels have been observed in sim-
ilarly supplemented individuals and these concentrations 
were shown to be antiproliferative in fibroblast cultures 
 [5, 14] .
 Phacotrabeculectomy and trabeculectomy outcome 
did not differ between   -tocopherol-supplemented indi-
viduals and the placebo group. Therefore, daily oral in-
take of up to 300 mg   -tocopherol (  -tocopheryl acetate) 
seems unlikely to have a relevant beneficial antiscarring 
effect in glaucoma-filtering procedures. Subconjunctival 
injection might at best be an alternative application meth-
od to be taken into consideration for future studies.
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Table 2. Distribution of early postoperative complications in the 
-tocopheryl-acetate- and placebo-treated groups 
-To-
copherol
(n = 19)
Control
(n = 20)
p
value1
Wound leak (positive Seidel test) 3 3 1.000
Hypotony (≤5 mm Hg) at week 2 3 3 1.000
Peripheral choroidal detachment 2 0 0.231
Flat anterior chamber 1 0 0.487
Total number of eyes with
complications 7 (37%) 4 (20%) 0.301
More than one complication can be found in the same eye.
1 Fisher’s exact test (two-tailed p) and 2 test.
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